Curriculum Vitae

Stephen James Mattichak, MD,

FACC, FSCAI, SVM

Home Address: **** ******** *****

Midland, MI 48640

Contact Information: ad1m0i@r.postjobfree.com

989-***-****

Board Certifications: American Board of Internal Medicine

Internal Medicine 2000

American Board of Internal Medicine

Cardiovascular Disease 2005

Recertification Cardiovascular Disease 2015

Participating in ABIM MOC and CMP

American Board of Internal Medicine

Interventional Cardiology 2006

Recertification Interventional Cardiology 2016

Participating in ABIM MOC and CMP

Work History: MyMichigan Healthcare

MyMichigan Interventional Cardiology

2660 Sugnet Road

Midland, MI 48670

May 15, 2023 to current

Director, Becky Boyce

McLaren Medical Group

McLaren Northern Michigan

Interventional Cardiology and Vascular Medicine

560 W. Mitchell St

Petoskey, MI 49770

August 1, 2022 to May 6, 2023

Paragon Cardiology Consulting

CEO/Owner/Independent Contractor

5602 Pondview Drive

Midland, MI 48640

September 1, 2021 to Current

McLaren Medical Group

McLaren Northern Michigan

Interventional Cardiology and Vascular Medicine/Endovascular

560 W. Mitchell St

Petoskey, Michigan 49770

September 1, 2020 to September 3, 2021

Comphealth

Locum Tenens Interventional Cardiology

Sanford, Bemidji

Bemidji, MN

April 2022 thru August 2022

CompHealth

Locum Tenens Interventional Cardiology

Bay Area Hospital

Coos Bay, OR

May 2020 thru August 2020;

September 2021 thru August 2022

Vascular Health Clinics

Interventional Cardiology and Endovascular Peripheral

2125 Ridgewood Drive

Midland, MI 48642

989-CLINICS

December 1, 2017 to August 1, 2020

Gap from Flint Cardiology Consultants for Insurance credentialing

Delta Locums

Locum Tenens Interventional Cardiology

Centura Mercy Hospital

Durango, CO

September thru December 2019

Flint Cardiovascular Consultants

Interventional Cardiology

4455 Town Center Parkway

Flint, MI 48532

October 14, 2016 to October 22, 2017

McLaren Medical Group

McLaren Bay Heart and Vascular

Bay Regional Medical Center d/b/a McLaren Bay Region

January 2009 to October 12, 2016

Michigan Cardiovascular Institute, Saginaw, MI

Interventional Cardiology and Clinical Cardiology

August 2006 to January 2009

IPC, The Hospitalist Company

Internal Medicine/Hospitalist Medicine

July 2000 thru December 2001

St. Louis, MO

Licensure: US DEA License for medical practice, State of Michigan

US DEA License for locum assignment-transferrable

Physician, State of Michigan Medical Board

Physician, Interstate Medical License Compact, Qualification Active thru February 2024

Physician, State of Utah Medical Board

Physician, State of Colorado Medical Board

Physician, State of Ohio Medical Board

Physician, State of Kentucky Medical Board

Physician, State of Minnesota Medical Board

Physician, State of Oregon Medical Board-Locum License

Michigan State Board of Pharmacy

Education: Doctor of Medicine 7/1993-6/1997

Wayne State University School of Medicine

Detroit, Michigan

Bachelor of Arts 8/1989-6/1993

Graduate, Albion College Honors Program

Graduate, Gerald R. Ford Institute for Public Service

Graduate Medical Education:

Interventional Cardiology Fellowship 7/2005-6/2006

William Beaumont Hospital

Royal Oak, Michigan

Adult Clinical Cardiology Fellowship 7/2002-6/2005

William Beaumont Hospital

Royal Oak, Michigan

Internal Medicine-Categorical Training 7/1997-6/2000

Emory University School of Medicine

Atlanta, Georgia

Hospital Affiliations: MyMichigan Medical Center, Midland, Michigan

Active Staff

McLaren Northern Michigan, Petoskey, Michigan

Active Staff

Sanford Healthcare, Bemidji, MN

Active Staff

Marlette Regional Hospital, Marlette, MI

Consulting Staff

Professional Societies: American Collge of Cardiology FACC

Society of Cardiac Angiography and Intervention FSCAI

Society of Vascular Medicine

Michigan State Medical Society

Procedural Volume: Over 16 years of interventional cardiology practice:

Proficiencies: Over 100 PCI annual

Protected PCI/High Risk PCI, Primary and Rescue PCI

CTO Coronary and peripheral

Coronary IVL Shockwave, Peripheral IVL Shockwave

Rotablator/Orbital atherectomy

Laser ELCA Phillips, 0.9 mm/1.4 mm Coronary, Peripheral laser

IVUS/OCT

iFR/RFR

Radial and Femoral Interventional Competency

IABP

Impella CP single and multisite access

R Pella insertion for RV shock

ASD and PFO closure for CVA/Shunt

Gore Cardioform proficient with over 35 implants

Vascular medicine and Vascular Non-invasive

Peripheral Diagnostic and Endovascular Interventions

Laser, directional atherectomy, angioplasty, IVL, stenting

Pedal and RP, conventional femoral

PERT Team, Inari/Penumbra/Ekos

DVT Inari/Penumbra

May Thurner

Loop Recorder Implant and Explant

Echocardiogram and TEE

Stress ECG/Stress Echocardiogram/Nuclear Stress

BLS/ACLS Certification

Appointments: Associate Professor, MSU School of Medicine

June 2023 to current

Associate Professor, CMU School of Medicine

June 2023 to current

Coordinator, Regional STEMI Network MyMichigan Health

Chief, Division of Cardiology

Bay Regional Medical Center d/b/a McLaren Bay Region

2010-2012, 2015-2017

Vice Chief, Division of Cardiology,

Bay Regional Medical Center 2008-2010

Co-Medical Director, Echocardiography Laboratory

Bay Regional Medical Center

2008 thru Present

Co-Director, Cardiovascular Research,

Bay Regional Heart and Vascular

Institutional Review Board, 2010-2011

Bay Regional Medical Center

Pharmacy and Therapeutics Committee, Bay Regional Medical Center

Clinical Research: Target FireHawk Stent study

Subinvestigator

McLaren Northern Michigan 2022- ongoing

Zeus Study

Subinvestigator

McLaren Northern Michigan 2022- ongoing

Institutional Principal Investigator, Cogentis Pharmaceutical

Randomized study of clopidogrel versus clopidogrel and omeprazole. Bay Regional Medical Center. (2007-2008)

Sub-Investigator, Sapphire WW, Carotid Stent Registry,

Bay Regional Medical Center. (2007-2008)

Sub-Investigator, Amethyst, Medtronic, Embolic Protection for saphenous vein graft intervention. Bay Regional Medical Center. (2007-2008).

Sub-Investigator, Spirit IV, Abbott Vascular, randomized study of

drug eluting Xience V versus Taxus, Bay Regional Medical Center. (2007-2008).

Sub-Investigator, Tracer, randomized study of complement inhibitor in acute coronary syndrome, Bay Regional Medical Center (2008-2009).

Sub-Investigator, Ascend-HF, randomized study of Natrecor versus loop diuretic for treatment of decompensated heart failure,

Bay Regional Medical Center (2007-2008).

Sub-Investigator, ALECARDIO, Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary (ACS) event and type 2 diabetes mellitus (T2D), McLaren Bay Region, (2010-2014).

Sub-Investigator, ALERTS, AngeLmed for Early Recognition and Treatment of STEMI Study, Angel Medical Systems, McLaren Bay Region (2012-Present).

Sub-Investigator, CHOICE, Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The Collection Of

Clinical Evidence, Abbott Vascular, Bay Regional Medical Center, 2009-2012.

Sub-Investigator, HCRI-DAPT, A Prospective, multi-center, randomized, double-blind, trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions. Harvard Clinical Research Institute, Bay Regional Medical Center (2009-Present).

Sub-Investigator, ORBIT-AF, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, Johnson and Johnson, McLaren Bay Region, (2010-present).

Sub-Investigator, RESOLUTE, A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of DE NOVO Native Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25mm to 4.2mm Medtronic, Bay Regional Medical Center (2009-Present)

Sub-Investigator, SELECT-ACS, A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of 2 Doses of RO4905417 (R1512) Administered to Patients with Non ST-Elevation Myocardial Infarction (Non-STEMI) undergoing Percutaneous Coronary Intervention (PCI),

Roche, Bay Regional Medical Center, (2011-2012).

Sub-Investigator, SPIRIT PRIME, A Clinical Evaluation of the XIENCE PRIME™ and XIENCE PRIME™ LL Everolimus Eluting Coronary Stent System. Abbott Vascular, McLaren Bay Region. (2009-2013)

Sub-Investigator, TRANSLATE-ACS, Observational Study Description H7T-US-B007(1) - Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome, Lilly, McLaren Bay Region, (2011-2014).

Sub-Investigator, TRILOGY ACS, A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed. Eli-Lilly, McLaren Bay Region (2009-2012)

Sub-Investigator, XIENCE V USA, a prospective, open-label, multi-center, observational, single arm registry to evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings. Abbott Vascular, McLaren Bay Region (2008-2013)

Sub-Investigator, XIENCE V USA DAPT, A prospective, multi-center, randomized, double-blind AV-DAPT cohort to assess the effectiveness and safety of 12 versus 30 months of DAPT in patients undergoing percutaneous coronary intervention (PCI) with XIENCE V placement for the treatment of coronary artery lesions. Abbott Vascular, McLaren Bay Region (2009-2013)

Sub-Investigator, ABSORB III RCT, A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions. Abbott Vascular, McLaren Bay Region, (2013-Present).

Sub-Investigator, GLAGOV, A Double-Blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG-145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization. Amgen, McLaren Bay Region (2013-Present)

Sub-Investigator, GLORIA-AF, Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients with Atrial Fibrillation.

Boehringer Ingelheim, McLaren Bay Region (2012-Present).

Sub-Investigator, GRAND_306, A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events. Takeda, McLaren Bay Region (2012-2014).

Sub-Investigator, MACE, Multi-center Prospective Study to Evaluate Outcomes of Moderate to Severely Calcified Coronary Lesions, Cardiovascular Systems Inc, McLaren Bay Region (2013-Present).

Sub-Investigator, ORBIT-AF II, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, Janssen Scientific Affairs, McLaren Bay Region (2013-Present).

Sub-Investigator, REGULATE-PCI, A Randomized, Open-label, Multi-center, Active-controlled, Parallel Group Study to Determine the Efficacy and Safety of the REG1 Anticoagulation System compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention, Regado Biosciences, McLaren Bay Region (2013-Present).

Publications: Mattichak SJ, Dixon SR, Shannon F, Boura JA, Safian RD, Failed percutaneous coronary intervention: A decade of experience in 21,000 patients. Catheterization and Cardiovascular Interventions 71:2, 2008

Mattichak SJ, Dixon SR, Safian RD, Hanzel GS, Boura JA, O’Neill WW, Eligibility for use of proximal or distal embolic protection devices during percutaneous intervention for acute myocardial infarction, Journal of Interventional Cardiology 18:4, 2005.

Mattichak SJ, Harjai KJ, Dutcher JR, Boura JA, Stone G, Brodie BR, O’Neill WW, Grine CL, Left ventricular remodeling and systolic deterioration in acute myocardial infarction: Finding of the Stent-PAMI study, Journal of Interventional Cardiology 18:4, 2005.

Mattichak SJ, Reed PS, Kahn JK, O’Neill WW, Evaluation and safety of warfarin in combination with antiplatelet therapy for patients with coronary stents after acute myocardial infarction, Journal of Interventional Cardiology, 2004.

Contact this candidate